Zymeworks Business Summary

Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid "royalty-driven" and asset-aggregation model, leveraging its proprietary Azymetric™ and ZymeLink™ platforms to develop multifunctional biotherapeutics. The company’s primary business segments include a portfolio of licensed healthcare assets—most notably the HER2-targeted bispecific antibody Ziihera (zanidatamab) and the T-cell engager pasritamig—and an internal R&D pipeline focused on antibody-drug conjugates (ADCs) for oncology and inflammatory diseases. Revenue is primarily derived from upfront licensing fees, milestone payments, and tiered royalties from global partners such as Jazz Pharmaceuticals, BeiGene, and Johnson & Johnson. In the competitive landscape, Zymeworks contends with major oncology players like Roche, BioAtla, and Immunocore, positioning itself as a specialized platform innovator that mitigates traditional biotech risk by aggregating high-value, partnered clinical assets alongside its wholly-owned discovery engine. Founded in 2003 by Dr. Ali Tehrani and Dr. Jayarama Akkiraju, Zymeworks is currently led by Chair and CEO Kenneth Galbraith, a veteran executive who previously served as CFO of QLT and held leadership roles at Syncona and Five Corners Capital. The executive team was recently reshaped in early 2026, with Mark Hollywood, formerly of ZymoGenetics (BMS) and Amgen, promoted to Executive Vice President and Chief Operating Officer, and Dr. Sabeen Mekan, a former Gilead Sciences and Daiichi Sankyo executive, assuming the role of Senior Vice President and Chief Medical Officer. The company’s strategic direction is supported by a streamlined nine-member board that includes recent appointee Brian Cherry (formerly of Oak Hill Capital) and Oleg Nodelman of EcoR1 Capital. Notable institutional investors include Renaissance Technologies, Dimensional Fund Advisors, and Federated Hermes, reflecting a strong capital base as the company executes its 2026 strategy of royalty growth and strategic acquisitions.